Voyager Therapeutics Inc.’s VYGR, +24.30% stock gained 16.8% in premarket trading on Tuesday after the gene therapy company said it inked a deal with Novartis [n: nvs] worth up to $1.7 billion. Novartis will pay $54 million upfront to license Voyager’s novel adeno-associated virus (AAV) capsids for use with the gene therapies it’s developing. There are several additional milestones included in the deal that would bring the total value up to $1.7 billion. Voyager’s stock is down 28.5% over the past year, while the broader S&P 500 SPX, -0.87% is up 14.2%.
View Article Origin Here
